SEEMINGLY SIMPLE questions about aspirin elude answers despite decades of study by clinical scientists. Soon, 35 years will have elapsed since the platelet-inhibiting properties of aspirin were reported,1,2 25 years since its first trial in secondary disease prevention,3 and 10 years since the first negative report in primary stroke prevention.4 Thousands of patients have been randomized in primary and secondary stroke prevention studies, but important questions persist.
Barnett HJM, Eliasziw M. Aspirin Benefit Remains Elusive in Primary Stroke Prevention. Arch Neurol. 2000;57(3):306-308. doi:10.1001/archneur.57.3.306